Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program
Authors
Keywords
-
Journal
ADVANCES IN THERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-22
DOI
10.1007/s12325-020-01366-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis
- (2019) Stefan Schreiber et al. Journal of Crohns & Colitis
- OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM
- (2019) C Yzet et al. Journal of Crohns & Colitis
- Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease
- (2019) Soo-Young Na et al. Gut and Liver
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tu2006 - Etrolizumab Induction Therapy Improves Histologic Outcomes in Anti-TNF-Failed Patients with Ulcerative Colitis: Results from the Hickory Open-Label Induction Cohort
- (2018) David T. Rubin et al. GASTROENTEROLOGY
- 20 ETROLIZUMAB IMPROVED ENDOSCOPIC SCORE, PATIENT-REPORTED OUTCOMES, AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE UC WHO HAD FAILED TNF ANTAGONIST THERAPY: THE HICKORY OPEN-LABEL INDUCTION (OLI) COHORT
- (2018) Laurent Peyrin-Biroulet et al. GASTROENTEROLOGY
- P132 Analysis of various central endoscopy reading methodologies in the BERGAMOT exploratory induction cohort evaluating etrolizumab in Crohn’s Disease
- (2018) W Reinisch et al. Journal of Crohns & Colitis
- Gut-selective integrin-targeted therapies for inflammatory bowel disease
- (2018) Christopher A Lamb et al. Journal of Crohns & Colitis
- The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohnʼs Disease Effector T Cells In Vivo
- (2017) Sebastian Zundler et al. INFLAMMATORY BOWEL DISEASES
- Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease
- (2017) Magali Lemaitre et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Late breaking abstracts
- (2017) United European Gastroenterology Journal
- Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis
- (2016) Gaik W. Tew et al. GASTROENTEROLOGY
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
- (2015) L Peyrin-Biroulet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up
- (2015) Robert V Bryant et al. GUT
- Development and validation of a histological index for UC
- (2015) Mahmoud H Mosli et al. GUT
- Development and validation of the Nancy histological index for UC
- (2015) Aude Marchal-Bressenot et al. GUT
- A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity
- (2014) R. Khanna et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Patient-Reported Outcomes as Primary End Points in Clinical Trials of Inflammatory Bowel Disease
- (2014) Nicolas Williet et al. Clinical Gastroenterology and Hepatology
- An endoscopic Mayo score of 0 is associated with a lower risk of colectomy than a score of 1 in ulcerative colitis
- (2014) Claire Manginot et al. GUT
- Systematic review: Histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiative
- (2014) R.V. Bryant et al. Journal of Crohns & Colitis
- Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
- (2014) Séverine Vermeire et al. LANCET
- Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials
- (2013) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
- (2011) Jean Frédéric Colombel et al. GASTROENTEROLOGY
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started